12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls

Antidotes are specialized pharmacological agents that directly neutralize, antagonize, or circumvent the toxic mechanisms of specific xenobiotics. Although supportive care forms the foundation of clinical toxicology, timely administration of targeted antidotes can immediately reverse life-threatening physiological collapse, arrest irreversible metabolic and cellular injury, and reduce critical care utilization. The Specialist in Poison Information (CSPI) must master the precise molecular mechanisms, dosing strategies, endpoint-driven titration parameters, and safety warnings for all core antidotes.

---

1. Naloxone (Opioid Receptor Antagonist)

Naloxone is a pure, competitive antagonist at central and peripheral mu (μ), kappa (κ), and delta (δ) opioid receptors, displaying the highest binding affinity for the μ-opioid receptor. It displaces endogenous and exogenous opioids without exerting any intrinsic agonist activity.

Naloxone Titration Hierarchy:
Bradypnea (< 8-10 breaths/min) + Hypercapnia + Pinpoint Miosis
                            │
                            ▼
Low-Dose Titration: 0.04 to 0.1 mg IV Boluses Every 2-3 Minutes
  (Avoid 2.0 mg IV pushes in opioid-dependent patients)
                            │
                            ▼
Target Endpoint Achieved: Spontaneous RR 10-14/min + Adequate Tidal Volume
  (Patient may remain somnolent; full alert awakening NOT required)
                            │
                            ▼
Anticipate Recurrence: Naloxone Half-Life (30-90 min) << Long-Acting Opioids (6-36 hr)
  Continuous Infusion Rate = 2/3 of Successful Resuscitation Dose per Hour

Titration Pearls and Administration Regimens

• Primary Titration Endpoint: The goal of naloxone therapy is adequate spontaneous alveolar ventilation (respiratory rate 10 to 12 breaths/min with normal chest excursion and resolution of hypoxia), NOT complete neurological wakefulness.
• Low-Dose Titration Strategy: In non-arrest patients with spontaneous circulation, administer 0.04 to 0.1 mg IV initially. Doubling the dose every 2 to 3 minutes (0.04 mg → 0.08 mg → 0.16 mg → 0.4 mg) safely reverses hypoventilation while avoiding precipitated acute withdrawal.
• High-Dose Indications: Patients presenting in cardiac arrest, extreme hypoxemic collapse, or following synthetic fentanyl analogue exposures often require immediate boluses of 1.0 to 2.0 mg IV to overcome high-potency receptor occupancy.
• The Re-Sedation Hazard & Continuous Infusion: Naloxone has an elimination half-life of only 30 to 90 minutes, whereas most opioids (methadone, extended-release oxycodone, buprenorphine) have half-lives extending from 6 to 36 hours. To prevent recurrent fatal hypoventilation: $\text{Continuous Infusion Hourly Rate} = \frac{2}{3} \times \text{Total Dose Required to Reverse Respiratory Depression}$
• Complications of Over-Naloxone Administration: Rapid large-dose boluses (e.g., 2 mg IV push in an opioid-dependent adult) trigger an explosive sympathetic surge: massive catecholamine release causing tachycardia, severe hypertension, violent psychomotor agitation, acute non-cardiogenic pulmonary edema, and emesis with fatal pulmonary aspiration.

---

2. N-Acetylcysteine (NAC) (Acetaminophen Antidote)

N-Acetylcysteine (NAC) is the definitive antidote for acetaminophen hepatotoxicity. It protects hepatocytes through multiple distinct mechanisms:

1. Serves as a precursor for intracellular glutathione synthesis by providing cysteine.
2. Directly binds and detoxifies N-acetyl-p-benzoquinone imine (NAPQI) by serving as a glutathione substitute.
3. Directly reduces NAPQI back to acetaminophen via non-enzymatic electron donation.
4. Acts as a potent antioxidant, free-radical scavenger, and microvascular inotrope that improves cerebral perfusion and blunts multiorgan failure in established toxic liver injury.

Dosing Protocols: Intravenous vs. Oral

Non-IgE Anaphylactoid Reactions with IV NAC

Approximately 10% to 20% of patients receiving rapid IV NAC loading develop non-allergic anaphylactoid reactions mediated by direct, concentration-dependent histamine release from mast cells and basophils, independent of IgE antibodies.

• Manifestations: Flushing, pruritus, urticaria, angioedema, bronchospasm, and rarely hypotension (typically peaking at the end of the 60-minute loading infusion).
• Management Algorithm:
  1. Immediately stop the IV NAC infusion.
  2. Administer IV diphenhydramine (25 to 50 mg) and an H2 blocker such as famotidine. If bronchospasm is present, administer albuterol nebulizers and methylprednisolone.
  3. Once flushing and hives resolve (typically within 30 to 60 minutes), restart IV NAC at the previous rate. Anaphylactoid reactions rarely recur once the high initial peak concentration has cleared.

Definitive Stopping Criteria for NAC

Never discontinue NAC simply because the 21-hour protocol bag is empty. NAC must be continued until all of the following laboratory parameters are met:

1. Serum acetaminophen concentration is undetectable (< 10 mcg/mL or below assay limit).
2. Serum AST and ALT are normal or clearly declining on two consecutive serial measurements.
3. The patient is clinically well, the INR is below 2.0, and there is no encephalopathy.

---

3. Atropine and Pralidoxime (Cholinesterase Inhibitor Antidotes)

Organophosphates and carbamate insecticides phosphorylate the serine hydroxyl residue at the active catalytic site of acetylcholinesterase (AChE), blocking acetylcholine breakdown and flooding muscarinic, nicotinic, and central synapses.

Cholinergic Poisoning Antidote Dual-Pathway:
              [Excess Intraluminal Acetylcholine]
                 │                             │
                 ▼                             ▼
      [Muscarinic Synapses]          [Nicotinic Synapses (NMJ)]
                 │                             │
                 ▼                             ▼
    Bronchorrhea, Bronchospasm,      Muscle Fasciculations, Tremors,
    Bradycardia ('Killer B's')       Diaphragmatic Flaccid Paralysis
                 │                             │
                 ▼                             ▼
        TITRATE ATROPINE               ADMINISTER PRALIDOXIME
(Competitive Muscarinic Antagonist)   (Reactivates Phosphorylated AChE)

Atropine: Muscarinic Receptor Antagonism

• Mechanism: Competitive antagonist at postganglionic muscarinic acetylcholine receptors (M₁ through M₅). It exerts zero effect on nicotinic receptors at the neuromuscular junction.
• Dosing Regimen: Adult loading dose is 1 to 3 mg IV (pediatric: 0.02 to 0.05 mg/kg IV). If no clinical improvement occurs within 3 to 5 minutes, double the dose (e.g., 2 mg → 4 mg → 8 mg → 16 mg → 32 mg) every 3 to 5 minutes until atropinization is reached.
• The Cardinal Atropinization Endpoints: Titrate atropine strictly to the resolution of pulmonary muscarinic excess:
  1. Clear lung sounds with complete cessation of bronchorrhea and tracheobronchial bubbling.
  2. Relief of bronchospasm and resistance on mechanical ventilation.
  3. Heart rate > 80 bpm with systolic blood pressure > 80 to 90 mmHg.
• The Mydriasis Trap: Never titrate atropine to pupil size! Pupils may remain pinpoint or dilate erratically due to sympathetic ganglionic firing. Dilated pupils with wet, gurgling lungs mean the patient is drowning in secretions and urgently requires more atropine.

Pralidoxime (2-PAM): Acetylcholinesterase Reactivator

• Mechanism: A nucleophilic oxime that attaches to the anionic site of acetylcholinesterase, forms a covalent bond with the organophosphate inhibitor, and hydrolyzes the phosphate-enzyme complex, freeing the functional enzyme.
• Target: Primarily reverses nicotinic neuromuscular blockade—terminating fasciculations, restoring diaphragmatic muscle strength, and reversing autonomic ganglionic dysfunction.
• Dosing: Adult dose: 1 to 2 g IV infused over 30 minutes, followed immediately by a continuous infusion of 400 to 500 mg/hr (pediatric: 20 to 50 mg/kg load over 30 min, then 10 to 20 mg/kg/hr continuous infusion). Rapid bolus administration can trigger transient hypertension, laryngospasm, and cardiac arrest.
• The 'Aging' Phenomenon: With time, the organophosphate-enzyme conjugate undergoes non-enzymatic loss of an alkyl side chain ('aging'). Once aged, the bond is irreversible, and pralidoxime can no longer reactivate the enzyme. 2-PAM must be started early before aging occurs (which ranges from minutes with soman to hours or days with common insecticides).

---

4. Physostigmine (Anticholinergic Antidote)

Physostigmine is a reversible carbamate inhibitor of acetylcholinesterase. Because it possesses an uncharged tertiary amine structure, it readily crosses the lipophilic blood-brain barrier to reverse both central anticholinergic delirium and peripheral muscarinic blockade (unlike quaternary amines like neostigmine or pyridostigmine, which remain excluded from the central nervous system).

Clinical Indications & Dosing

• Indications: Severe central anticholinergic delirium, unmanageable agitation requiring physical restraints, and severe hyperpyrexia refractory to benzodiazepines resulting from pure antimuscarinics (diphenhydramine, benztropine, atropine, Datura stramonium).
• Dosing: Administer 1 to 2 mg IV slow push over 5 minutes in adults (pediatric: 0.02 mg/kg, maximum 0.5 mg). Rapid IV boluses can provoke severe bradycardia, hypersalivation, and cholinergic convulsions. Therapeutic effects appear within 5 to 15 minutes, lasting 30 to 60 minutes.

Absolute Contraindications and Safety Warnings

• Tricyclic Antidepressants (TCAs): Absolute contraindication. Co-ingestion of TCAs or agents with significant myocardial sodium channel blockade results in sudden, refractory asystolic cardiac arrest when physostigmine is administered, driven by combined cholinergic bradycardia and intraventricular conduction block.
• Electrocardiographic Contraindications: Prolonged QRS duration (> 100 ms), rightward terminal axis shift in aVR, or PR prolongation.
• Mandatory Bedside Safety Measure: Always have atropine (0.5 to 1.0 mg) drawn up at the bedside before injecting physostigmine to immediately treat iatrogenic cholinergic excess.

---

5. High-Dose Insulin Euglycemia Therapy (HIET), Glucagon, and Calcium

Cardiotoxic shock from severe calcium channel blocker (CCB) and beta-adrenergic antagonist overdose presents with refractory bradycardia, advanced AV nodal block, and low-output cardiogenic shock.

Myocardial Metabolism in CCB / Beta-Blocker Shock:
Normal Stress State:   Myocytes oxidize Free Fatty Acids (FFA) for ~80% of ATP
Toxic Shock State:     Myocytes stall; require Glucose as sole metabolic substrate
                         │
                         ▼
Severe CCB Toxicity Blocks Pancreatic L-Type Channels ──► Halts Endogenous Insulin Release
                         │
                         ▼
Myocardial Starvation + Vasoplegia + Loss of Calcium-Mediated Contractility
                         │
                         ▼
         HIGH-DOSE INSULIN EUGLYCEMIA THERAPY (HIET)
• Overcomes insulin resistance  • Drives glucose into poisoned myocytes
• Potent positive inotrope      • Dilates microvasculature & restores perfusion

1. High-Dose Insulin Euglycemia Therapy (HIET)

• Mechanism: Stressed myocardium switches from utilizing free fatty acids to glucose as its primary fuel. CCBs and beta-blockers impair pancreatic insulin secretion and induce profound peripheral insulin resistance. HIET provides massive concentrations of insulin that force glucose uptake into myocardial cells, restoring high-energy phosphate synthesis, improving sarcoplasmic reticulum calcium handling, and providing potent positive inotropy without increasing myocardial oxygen demand.
• HIET Protocol:
  1. Insulin Bolus: 1 unit/kg IV regular insulin administered concurrently with a dextrose bolus (25 to 50 g IV, e.g., 50 mL of D50W in adults; 0.5 g/kg in children).
  2. Insulin Maintenance Infusion: 1 unit/kg/hr regular insulin, titrated rapidly upward every 15 to 30 minutes up to 2 to 10 units/kg/hr until target cardiac output and blood pressure are restored.
  3. Euglycemia Maintenance: Co-infuse concentrated dextrose (D10W or D20W via central line) titrated to maintain blood glucose between 100 and 200 mg/dL. Check bedside glucose every 15 to 30 minutes initially.
  4. Potassium Management: Insulin drives potassium into cells. The shift is intracellular, so total body potassium is not depleted: many protocols tolerate potassium around 2.8 to 3.2 mEq/L, supplementing cautiously only if it falls below about 2.8 mEq/L or dysrhythmias appear, to avoid rebound hyperkalemia when insulin stops.

2. Glucagon

• Mechanism: Bypasses beta-adrenergic receptors by binding to specific glucagon G-protein coupled receptors, directly stimulating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). This augments intracellular calcium release to improve heart rate and myocardial contractility.
• Dosing: Adult dose: 3 to 10 mg IV slow push over 3 to 5 minutes (pediatric: 50 to 150 mcg/kg). If hemodynamic response occurs, initiate a continuous infusion at the hourly dose that produced the initial response (typically 2 to 5 mg/hr).
• Adverse Effects: Profuse nausea, intractable vomiting (aspiration hazard), and hyperglycemia.

3. Calcium Salts

• Mechanism: Increases the extracellular-to-intracellular concentration gradient, overcoming competitive L-type calcium channel inhibition on vascular smooth muscle and cardiac myocytes.
• Dosing: Calcium chloride (10%): 1 to 2 g (10 to 20 mL) IV via central venous catheter (risk of severe tissue necrosis with extravasation); OR Calcium gluconate (10%): 3 to 6 g (30 to 60 mL) IV peripherally. Repeat every 10 to 15 minutes up to 3 to 4 doses, targeting ionized calcium at 1.5 to 2.0 times normal.

---

6. Digoxin Immune Fab (DigiFab)

Digoxin Immune Fab fragments are purified, sterile, monovalent Fab segments of sheep antidigoxin antibodies. They bind free intravascular digoxin and botanical cardenolides (oleander, foxglove, lily of the valley) with affinity greater than that of the Na⁺/K⁺-ATPase pump, pulling tissue-bound glycoside into the vascular compartment for renal excretion.

Dosing Strategies

• Empiric Resuscitation for Acute Cardiac Arrest or Hemodynamic Collapse: Administer 10 to 20 vials IV push immediately.
• Chronic Toxicity with Life-Threatening Hyperkalemia or Dysrhythmias: Administer 3 to 6 vials IV; each vial neutralizes approximately 0.5 mg of digitalis.
• Calculation Based on Known Steady-State Concentration: $\text{Dose in Vials} = \frac{\text{Serum Digoxin Concentration (ng/mL)} \times \text{Patient Weight (kg)}}{100}$
• Key Clinical Pearl: Once DigiFab is administered, standard total serum digoxin immunoassays become completely uninterpretable because they measure both free and Fab-bound inactive drug, reporting falsely astronomical levels.

---

7. Hydroxocobalamin and Cyanide Antidotes

Cyanide arrests aerobic respiration by binding with high affinity to the ferric (Fe³⁺) ion of cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain, causing catastrophic intracellular energy failure and profound lactic acidosis.

Hydroxocobalamin (Cyanokit - First-Line)

• Mechanism: Hydroxocobalamin contains a cobalt center that binds cyanide with higher affinity than cytochrome oxidase, forming non-toxic cyanocobalamin (vitamin B12), which is safely cleared renally.
• Dosing: Adult dose: 5 g IV infused over 15 minutes (pediatric: 70 mg/kg up to 5 g). A second 5 g dose can be administered for persistent shock or cardiac arrest.
• Advantages: Does not induce methemoglobinemia, making it the antidote of choice for smoke inhalation victims who may suffer concurrent carbon monoxide poisoning.
• Clinical Warnings & Assay Interferences: Imparts a deep, wine-red chromaturia and intense cutaneous erythema lasting up to 2 to 4 weeks. Causes profound interference with colorimetric clinical laboratory assays: falsely elevates carboxyhemoglobin, total bilirubin, and creatinine; triggers false-positive blood-leak alarms on hemodialysis circuits.

The Historical Cyanide Antidote Kit (Nitrites + Sodium Thiosulfate)

• Amyl Nitrite & Sodium Nitrite: Oxidize hemoglobin from ferrous (Fe²⁺) to ferric (Fe³⁺), generating methemoglobin. Methemoglobin strips cyanide from cytochrome oxidase to form cyanomethemoglobin.
• Sodium Thiosulfate: Serves as a sulfur substrate for the hepatic enzyme rhodanese, converting cyanide to non-toxic thiocyanate, which is excreted in urine.
• CRITICAL WARNING: Nitrites should be avoided in smoke inhalation victims. Inducing methemoglobinemia in a patient already compromised by carboxyhemoglobin fatally obliterates remaining oxygen-carrying capacity.

---

8. Methylene Blue (Methemoglobinemia Antidote)

Methemoglobin forms when hemoglobin's iron atom is oxidized from the ferrous (Fe²⁺) state to the ferric (Fe³⁺) state. Ferric iron cannot bind oxygen, and it shifts the remaining oxygen-hemoglobin dissociation curve to the left, suffocating tissue oxygen delivery.

Mechanism, Dosing, and Safety Warnings

• Mechanism: Methylene blue acts as an exogenous electron carrier. It is reduced by intracellular NADPH-dependent methemoglobin reductase to leukomethylene blue, which then non-enzymatically donates an electron to convert ferric (Fe³⁺) iron back to oxygen-carrying ferrous (Fe²⁺) iron.
• Dosing: Administer 1 to 2 mg/kg IV (0.1 to 0.2 mL/kg of 1% solution) infused over 5 minutes. Methemoglobin levels decline significantly within 30 to 60 minutes. May repeat once after 30 to 60 minutes if cyanosis and hypoxia persist.
• Absolute Contraindication: G6PD Deficiency: In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cells cannot generate sufficient NADPH via the hexose monophosphate shunt. Methylene blue is completely ineffective, acts as a severe oxidizing agent, and triggers catastrophic massive hemolytic anemia.
• Severe Drug Warning: Serotonin Syndrome: Methylene blue is a potent, reversible inhibitor of monoamine oxidase A (MAO-A). Administering methylene blue to a patient receiving selective serotonin reuptake inhibitors (SSRIs) or SNRIs can precipitate fatal Serotonin Syndrome.

---

9. Intravenous Lipid Emulsion 20% (ILE)

Intravenous Lipid Emulsion (ILE, 20% Intralipid) was developed to treat Local Anesthetic Systemic Toxicity (LAST) from bupivacaine, ropivacaine, and lidocaine, and is now utilized for refractory cardiotoxic shock from severe lipophilic drug overdoses (verapamil, diltiazem, beta-blockers, TCAs, bupropion).

Multimodal Mechanisms of 20% Intravenous Lipid Emulsion:
1. Lipid Sink / Partitioning: Creates intravascular lipid phase; extracts lipophilic drugs from tissue receptors
2. Metabolic Fuel: Provides abundant fatty acid substrates directly to ATP-depleted poisoned myocardium
3. Membrane Ion Channel Modulation: Directly activates myocardial L-type calcium and sodium channels

Clinical Administration Protocol

• Loading Bolus: Administer 1.5 mL/kg of 20% lipid emulsion IV bolus over 2 to 3 minutes.
• Continuous Infusion: Follow immediately with a continuous infusion of 0.25 mL/kg/min.
• Refractory Cardiac Arrest: Re-bolus 1.5 mL/kg every 3 to 5 minutes up to a maximum total dose of 10 to 12 mL/kg over the first 30 to 60 minutes.
• Laboratory & Procedural Interferences: Profound hypertriglyceridemia causes severe lipemia, interfering with clinical chemistry assays (electrolytes, enzymes, hematocrit) and clogging extracorporeal membrane oxygenation (ECMO) and hemodialysis filters.

---

10. Specialty Poison Center Antidotes

Fomepizole (4-Methylpyrazole)

• Mechanism: Potent, competitive inhibitor of alcohol dehydrogenase (ADH), displaying 8,000-fold higher affinity for ADH than ethanol. It prevents the biotransformation of ethylene glycol to toxic glycolic/oxalic acids and methanol to neurotoxic formic acid.
• Dosing Regimen: Loading dose: 15 mg/kg IV over 30 minutes. Maintenance dosing: 10 mg/kg IV every 12 hours for 4 doses, then increased to 15 mg/kg IV every 12 hours thereafter (due to self-induction of metabolism). When the patient undergoes hemodialysis, increase dosing frequency to every 4 hours.

Pyridoxine (Vitamin B6)

• Mechanism: Isoniazid (INH) and monomethylhydrazine (Gyromitra mushrooms) inactivate pyridoxal-5-phosphate, halting glutamic acid decarboxylase synthesis of gamma-aminobutyric acid (GABA), precipitating status epilepticus. Pyridoxine restores active pyridoxal-5-phosphate to reconstitute GABA synthesis.
• Dosing for INH: Administer gram-for-gram matching the ingested isoniazid dose (e.g., 5 g of INH = 5 g of IV pyridoxine). If the ingested dose is unknown, administer 5 g IV slow push (pediatric: 70 mg/kg, max 5 g).

L-Carnitine (Levocarnitine)

• Mechanism: Valproic acid toxicity depletes hepatic carnitine stores, inhibiting mitochondrial beta-oxidation of fatty acids and accumulating toxic 4-en-valproic acid and ammonia. L-Carnitine restores the carnitine shuttle, facilitating mitochondrial beta-oxidation and ammonia clearance.
• Dosing: Adult loading dose: 100 mg/kg IV (max 6 g) infused over 30 minutes, followed by 15 mg/kg IV every 4 hours until hyperammonemia, encephalopathy, and hepatotoxicity resolve.

Octreotide

• Mechanism: Synthetic somatostatin analogue that binds to somatostatin receptor subtype 2 (SSTR₂) on pancreatic beta-islet cells, hyperpolarizing the membrane, blocking calcium influx, and halting sulfonylurea-stimulated insulin exocytosis.
• Dosing: Adult dose: 50 mcg subcutaneously or IV every 6 hours (some protocols use 50 to 100 mcg every 6 to 12 hours; pediatric: 1 to 1.25 mcg/kg). Halts refractory rebound hypoglycemia caused by oral sulfonylureas (glipizide, glyburide, glimepiride).

---

Comprehensive Antidote Reference Matrix

---

Poison Center Case Scenario: Refractory Shock from Mixed Cardiotoxic Ingestion

A 58-year-old female presents to the emergency resuscitation bay 3 hours after ingesting forty 180 mg extended-release diltiazem tablets and thirty 50 mg metoprolol tablets in an intentional overdose. On arrival, the patient is obtunded, pale, cool, and diaphoretic. Vital signs are: blood pressure 64/38 mmHg, heart rate 34 beats/min (third-degree complete heart block on 12-lead ECG), respiratory rate 14 breaths/min, and blood glucose 342 mg/dL. Two liters of intravenous balanced crystalloid and 1 mg of IV atropine produce zero improvement in heart rate or blood pressure. The emergency team establishes peripheral norepinephrine and phenylephrine infusions at maximum rates with persistent shock.

Specialist in Poison Information Interventions

1. Recognize Cardiotoxic Shock Pathophysiology: The CSPI explains that severe CCB and beta-blocker toxicity causes profound electromechanical myocardial failure, systemic vasoplegia, and metabolic uncoupling. High-dose vasopressors alone increase cardiac afterload without improving contractility.
2. Immediate Antidotal Resuscitation Hierarchy:
   • Calcium Salts: Administer calcium chloride 10% (1 g IV central push) to increase extracellular calcium gradients.
   • High-Dose Insulin Euglycemia Therapy (HIET): Order an immediate loading bolus of regular insulin 1 unit/kg IV (70 units) withholding the dextrose bolus because the glucose is already 342 mg/dL, immediately followed by an insulin infusion at 1 unit/kg/hr (70 units/hr). The CSPI instructs the physician to titrate the insulin upward every 15 minutes by 1 unit/kg/hr up to 5 to 10 units/kg/hr until mean arterial pressure > 65 mmHg and cardiac index normalize.
   • Dextrose Co-Infusion: Initiate a central infusion of 10% or 20% dextrose titrated to maintain blood glucose between 100 and 200 mg/dL with point-of-care glucose testing every 15 minutes.
   • Potassium Safeguards: Do not aggressively treat hypokalemia down to 3.0 mEq/L, as insulin merely drives extracellular potassium into cells.
3. Adjunctive Therapy for Refractory Collapse: If cardiac index remains depressed despite HIET titration at 45 minutes, prepare for 20% Intravenous Lipid Emulsion (1.5 mL/kg bolus) and contact the regional extracorporeal life support team for Veno-Arterial ECMO consultation.